ESGO statement on the role of CA/125 measurement in follow-up of epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 22, Issue 1, 2012, Pages 175-

  Van Der Zee, Ate G J ^a   Colombo, Nicoletta ^b   Gitsch, Gerald ^b   Reed, Nicolas ^b   Amant, Frederic ^b   Cibula, David ^b   Kesic, Vesna I ^b   Kimmig, Rainer ^b   Lopes, Alberto D B ^b   Markowska, Janina ^b   Marth, Christian ^b   Radolakis, Alexander ^b   Salvesen, Helga ^b   Vaitkiene, Daiva ^b   Verheijen, René H M ^b   Zola, Paolo ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER THERAPY; EDITORIAL; FOLLOW UP; HUMAN; OVARY CANCER; PATIENT INFORMATION; PRIORITY JOURNAL; TREATMENT RESPONSE;

CA-125 ANTIGEN; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84858185102     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182261f15     Document Type: Editorial

References (2)

1. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376: 1155-1163.
2. Verheijen RHM, Cibula D, Zola P, et al. Cancer Antigen 125: Lost to Follow-Up?: A European Society of Gynaecological Oncology Consensus Statement. Int J Gynecol Cancer. 2012;22:170-174.